CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression

Yoshinori Yanai; Takeo Kosaka; Kohei Nakamura; Eriko Aimono; Kazuhiro Matsumoto; Shinya Morita; Shuji Mikami; Hiroshi Nishihara; Mototsugu Oya

doi:10.1111/cas.14672

CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression

Yoshinori Yanai, Takeo Kosaka, Kohei Nakamura, Eriko Aimono, Kazuhiro Matsumoto, Shinya Morita, Shuji Mikami, Hiroshi Nishihara, Mototsugu Oya

Research output: Contribution to journal › Article › peer-review

Abstract

Cyclin-dependent kinase 12 (CDK12), one of the key factors associated with DNA damage response pathways, is located on chromosome 17 proximal to Erb-B2 receptor tyrosine kinase 2 (ERBB2). In this report, CDK12 and ERBB2 coamplification was detected by targeted next-generation sequencing in two urothelial carcinomas. The staining intensity of the CDK12 and human epidermal growth factor receptor-2 proteins was associated with the prognosis of each urothelial carcinoma case. Our results suggest that CDK12 coamplification with ERBB2 might be associated with tumor aggressiveness and contribution to cancer pathogenesis. Therapies targeting CDK12 should be developed for these patients.

Original language	English
Pages (from-to)	4652-4655
Number of pages	4
Journal	Cancer science
Volume	111
Issue number	12
DOIs	https://doi.org/10.1111/cas.14672
Publication status	Published - 2020 Dec

Keywords

CDK12 amplification
DNA repair gene
ERBB2
prostate cancer
urothelial carcinoma

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/cas.14672

Cite this

@article{098ab7450b8f4a2492da3fd849fc2338,

title = "CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression",

abstract = "Cyclin-dependent kinase 12 (CDK12), one of the key factors associated with DNA damage response pathways, is located on chromosome 17 proximal to Erb-B2 receptor tyrosine kinase 2 (ERBB2). In this report, CDK12 and ERBB2 coamplification was detected by targeted next-generation sequencing in two urothelial carcinomas. The staining intensity of the CDK12 and human epidermal growth factor receptor-2 proteins was associated with the prognosis of each urothelial carcinoma case. Our results suggest that CDK12 coamplification with ERBB2 might be associated with tumor aggressiveness and contribution to cancer pathogenesis. Therapies targeting CDK12 should be developed for these patients.",

keywords = "CDK12 amplification, DNA repair gene, ERBB2, prostate cancer, urothelial carcinoma",

author = "Yoshinori Yanai and Takeo Kosaka and Kohei Nakamura and Eriko Aimono and Kazuhiro Matsumoto and Shinya Morita and Shuji Mikami and Hiroshi Nishihara and Mototsugu Oya",

note = "Funding Information: We thank Yoko Suzuki, Emmy Yanagida, and Hiroshi Yamada for technical assistance. This work was supported in part by a Grant‐in‐Aid for Scientific Research (#20H03817 to T.K) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and by a research grant to T. Kosaka from the Japan Urological Association. Publisher Copyright: {\textcopyright} 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.",

year = "2020",

month = dec,

doi = "10.1111/cas.14672",

language = "English",

volume = "111",

pages = "4652--4655",

journal = "Cancer Science",

issn = "1347-9032",

publisher = "Wiley-Blackwell",

number = "12",

}

TY - JOUR

T1 - CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression

AU - Yanai, Yoshinori

AU - Kosaka, Takeo

AU - Nakamura, Kohei

AU - Aimono, Eriko

AU - Matsumoto, Kazuhiro

AU - Morita, Shinya

AU - Mikami, Shuji

AU - Nishihara, Hiroshi

AU - Oya, Mototsugu

N1 - Funding Information: We thank Yoko Suzuki, Emmy Yanagida, and Hiroshi Yamada for technical assistance. This work was supported in part by a Grant‐in‐Aid for Scientific Research (#20H03817 to T.K) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and by a research grant to T. Kosaka from the Japan Urological Association. Publisher Copyright: © 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

PY - 2020/12

Y1 - 2020/12

N2 - Cyclin-dependent kinase 12 (CDK12), one of the key factors associated with DNA damage response pathways, is located on chromosome 17 proximal to Erb-B2 receptor tyrosine kinase 2 (ERBB2). In this report, CDK12 and ERBB2 coamplification was detected by targeted next-generation sequencing in two urothelial carcinomas. The staining intensity of the CDK12 and human epidermal growth factor receptor-2 proteins was associated with the prognosis of each urothelial carcinoma case. Our results suggest that CDK12 coamplification with ERBB2 might be associated with tumor aggressiveness and contribution to cancer pathogenesis. Therapies targeting CDK12 should be developed for these patients.

AB - Cyclin-dependent kinase 12 (CDK12), one of the key factors associated with DNA damage response pathways, is located on chromosome 17 proximal to Erb-B2 receptor tyrosine kinase 2 (ERBB2). In this report, CDK12 and ERBB2 coamplification was detected by targeted next-generation sequencing in two urothelial carcinomas. The staining intensity of the CDK12 and human epidermal growth factor receptor-2 proteins was associated with the prognosis of each urothelial carcinoma case. Our results suggest that CDK12 coamplification with ERBB2 might be associated with tumor aggressiveness and contribution to cancer pathogenesis. Therapies targeting CDK12 should be developed for these patients.

KW - CDK12 amplification

KW - DNA repair gene

KW - ERBB2

KW - prostate cancer

KW - urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85093529490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85093529490&partnerID=8YFLogxK

U2 - 10.1111/cas.14672

DO - 10.1111/cas.14672

M3 - Article

C2 - 33038052

AN - SCOPUS:85093529490

SN - 1347-9032

VL - 111

SP - 4652

EP - 4655

JO - Cancer Science

JF - Cancer Science

IS - 12

ER -

CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this